Welcome to our dedicated page for Kineta news (Ticker: KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.
Kineta, Inc. (KA) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies. The company's primary asset, KVA12.1, is a VISTA blocking immunotherapy designed to enhance the body's immune response against cancer. Kineta is committed to transforming patients' lives through groundbreaking therapies that target the body's protein homeostasis network.
The proteostasis network is crucial for maintaining the body's natural balance of proteins, protecting against diseases such as Alzheimer's, emphysema, Huntington's disease, and type II diabetes. By developing novel small molecule therapeutics, Kineta aims to control this network, offering potential treatments for various genetic and degenerative disorders.
Kineta's recent achievements include the Phase 1/2 VISTA-101 trial of KVA12.1 in patients with solid cancer tumors, with clinical data announced in March 2024. The company continues to make progress with conference presentations and anticipates future milestones in the first quarter of 2024.
For more information, interested parties can contact:
- Jacques Bouchy, EVP Investor Relations & Business Development: jbouchy@kineta.us
- John Mullaly, LifeSci Advisors, LLC: jmullaly@lifesciadvisors.com
- Bruce Mackle, LifeSci Advisors, LLC: bmackle@lifesciadvisors.com
- General inquiries: info@kineta.us
Rhea-AI Summary
Kineta, Inc. reports stable disease in VISTA-101 trial, explores strategic alternatives after restructuring. Financial highlights show decreased cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
-
Rhea-AI Summary
Kineta, Inc. (KA) reports positive clinical trial results for KVA12123 in oncology, showing stable disease in monotherapy and combination cohorts with no dose-limiting toxicities. The company is exploring strategic alternatives to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.28%
Tags
-
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) announces a significant corporate restructuring to reduce expenses and preserve cash, including a workforce reduction and termination of enrollment in a clinical trial. The company is exploring strategic alternatives to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-63.72%
Tags
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) announces the presentation of new preclinical data on KVA12123, its anti-VISTA antibody, at the AACR Blood Cancer Discovery Symposium. The data focuses on treating Acute Myeloid Leukemia, with the poster presentation by Thierry Guillaudeux, Ph.D., Chief Scientific Officer. The event will take place on March 4-6, 2024, in Boston, Massachusetts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
-
Rhea-AI Summary
Kineta, Inc. (KA) announces its participation in upcoming investors conferences to present its novel immunotherapies in oncology. The Company will attend BIO CEO and Investor Conference, 10th Annual Immuno-Oncology 360 Conference, and Opal Group Family Office Winter Forum for presentations and 1:1 meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
-
Rhea-AI Summary
Kineta, Inc. (KA) will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024, to present recent clinical results of KVA12123, the company’s VISTA blocking immunotherapy for advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
Rhea-AI Summary
Kineta, Inc. announced that KVA12123, its novel VISTA blocking immunotherapy, has shown promising results in the VISTA-101 Phase 1/2 clinical trial. The drug cleared the first four monotherapy dose levels and the first cohort in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, with no dose limiting toxicities. The safety profile of KVA12123 supports advancing to higher doses in the monotherapy and combination cohorts of the study. The drug demonstrated dose proportional induction of pro-inflammatory biomarkers required for strong anti-tumor activity, and the clinical study is progressing on time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
-
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) to participate in the 13th Annual LifeSci Partners Corporate Access Event, showcasing potential growth in 2024 with significant progress on the clinical development of KVA12123, a novel VISTA immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
-
Rhea-AI Summary
Kineta, a clinical-stage biotechnology company focused on novel immunotherapies in oncology, announced the publication of preclinical data on KVA12123 in Frontiers in Immunology. KVA12123 shows strong single-agent anti-tumor activity while minimizing cytokine-related adverse events, recognizing a unique VISTA epitope and binding at neutral and acidic pH. Key results include high affinity binding to VISTA, specificity against VISTA with no cross-reactivity against other B7 family members, and the ability to reverse T cell suppression by myeloid-derived suppressor cells. KVA12123 is currently being evaluated in a Phase 1/2 VISTA-101 open-label clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (NCT05708950).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
Rhea-AI Summary
Kineta, a clinical-stage biotechnology company (Nasdaq: KA), will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors. The event will feature presentations from key opinion leaders in immuno-oncology, discussing the potential for VISTA blocking immunotherapy to reverse immunosuppression in the tumor microenvironment and drive anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
FAQ
What is the current stock price of Kineta (KA)?
The current stock price of Kineta (KA) is $0.5746 as of September 19, 2024.
What is the market cap of Kineta (KA)?
The market cap of Kineta (KA) is approximately 7.0M.
What does Kineta, Inc. specialize in?
Kineta, Inc. specializes in developing next-generation immunotherapies to treat various diseases, focusing on controlling the body's protein homeostasis network.
What is KVA12.1?
KVA12.1 is Kineta's primary asset, a VISTA blocking immunotherapy designed to enhance the immune response against cancer.
What diseases does Kineta aim to treat?
Kineta aims to treat genetic and degenerative disorders such as Alzheimer's, emphysema, Huntington's disease, and type II diabetes.
What recent achievements has Kineta made?
Kineta's recent achievements include the Phase 1/2 VISTA-101 trial of KVA12.1 in patients with solid cancer tumors, with clinical data announced in March 2024.
How can I contact Kineta, Inc. for more information?
For more information, you can contact Jacques Bouchy at jbouchy@kineta.us, John Mullaly at jmullaly@lifesciadvisors.com, Bruce Mackle at bmackle@lifesciadvisors.com, or send general inquiries to info@kineta.us.
What is the proteostasis network?
The proteostasis network is the body's system for maintaining the natural balance of proteins, protecting against various diseases.
What are proteostasis regulators?
Proteostasis regulators are novel therapies designed to control the proteostasis network and treat diseases related to protein imbalance.
What future milestones does Kineta anticipate?
Kineta anticipates significant milestones in the first quarter of 2024, including advancements in their clinical trials and presentations.
How does Kineta's VISTA blocking immunotherapy work?
Kineta's VISTA blocking immunotherapy, KVA12.1, works by inhibiting the VISTA protein, thereby enhancing the body's immune response against cancer.
Where can I find the latest news about Kineta, Inc.?
The latest news about Kineta, Inc. can be found through their investor relations contact, press releases, and updates on their official website.
Kineta, Inc.
Nasdaq:KA
KA Rankings
KA Stock Data
7.05M
12.26M
34.89%
6%
0.23%
Biotechnology
Pharmaceutical Preparations
United States of America
MERCER ISLAND